top of page

Roche’s ALK-positive NSCLC drug granted FDA breakthrough designation

This second alecensa breakthrough therapy designation granted is based on phase 3 J-ALEX study.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page